Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 4977 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

Table of Contents
Year : 2013  |  Volume : 17  |  Issue : 6  |  Page : 990-995

Imaging of non alcoholic fatty liver disease: A road less travelled

1 Department of Radiology, All India Institute of Medical Sciences, New Delhi, India
2 Department of Endocrinology, Excel Center, Guwahati, Assam, India

Date of Web Publication3-Dec-2013

Correspondence Address:
Chandan J Das
Department of Radiology, All India Institute of Medical Sciences, New Delhi 29
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.122606

Rights and Permissions

Non alcoholic fatty liver disease (NAFLD) is a spectrum that includes simple steatosis, nonalcoholic steatohepatitis and cirrhosis. It is increasingly emerging as a cause of elevated liver enzymes, cryptogenic cirrhosis and hepatocellular carcinoma. The morbidity and mortality related to NAFLD is expected to rise with the upsurge of obesity and type 2 diabetes mellitus. The need of the hour is to devise techniques to estimate and then accurately follow-up hepatic fat content in patients with NAFLD. There are lots of imaging modalities in the radiological armamentarium, namely, ultrasonography with the extra edge of elastography, computed tomography, and magnetic resonance imaging with chemical shift imaging and spectroscopy to provide an estimation of hepatic fat content.

Keywords: Chemical shift imaging, computed tomography, hepatic steatosis, MR spectroscopy, non alcoholic fatty liver disease, sonoelastography

How to cite this article:
Singh D, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J Endocr Metab 2013;17:990-5

How to cite this URL:
Singh D, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J Endocr Metab [serial online] 2013 [cited 2021 Jul 26];17:990-5. Available from: https://www.ijem.in/text.asp?2013/17/6/990/122606

   Introduction Top

Non alcoholic fatty liver disease (NAFLD) has today been recognized as the most common cause of abnormal liver function among adults in the United States. [1] It is a cause of liver disease to reckon with in the Indian population. Various epidemiological studies have placed the prevalence of NAFLD from 9% to 32% of general population in India. [2] NAFLD is a spectrum that includes simple steatosis and nonalcoholic steatohepatitis (NASH). It is increasingly emerging as a cause of elevated liver enzymes, cryptogenic cirrhosis, and hepatocellular carcinoma. In recent times, the prevalence of NAFLD has been increasing in the pediatric population, thereby increasing its overall impact. [3] Efforts are underway to develop novel therapies to combat this global problem. Liver biopsy has been the gold standard for determination of hepatic steatosis and accompanying changes. However, this procedure is invasive with several drawbacks. These limitations have prompted investigators to devise non-invasive, "painless", reliable alternatives to detect and quantify liver fat. There are a host of imaging modalities in the radiological armamentarium, namely, ultrasonography (USG) with the extra edge of elastography, computed tomography (CT), and magnetic resonance imaging (MRI) with chemical shift imaging (CSI) and spectroscopy to provide an estimation of hepatic fat content.

   Pathophysiology Top

Various mechanisms have been put forth to explain the pathogenesis of NASH. The "multiple hit" hypothesis is the most widely accepted. This proposes first "hit" as the development of hepatic macrosteatosis as a result of increased lipolysis and free fatty acid levels. The increase in the reduction of free fatty acid oxidation with insulin resistance leads to fatty acid accumulation. Several possible "second hits" may be oxidative stress from reactive oxygen species in the mitochondria and cytochrome P450 enzymes, endotoxins, cytokines, adipokines and environmental factors [Figure 1]. Central obesity with visceral fat and white adipose deposition is a major source of adipokines and cytokines. Adipokines released from white adipose tissue include adiponectin (protective), leptin (pro-fibrotic), and resistin (mediator of insulin resistance). The proinflammatory cytokines released from white adipose tissue include tumor necrosis factor alpha (TNF-α) and interleukin-6. [4]
Figure 1: Pathophysiology of non alcoholic fatty liver disease

Click here to view

   Imaging Modalities Top


USG is a safe, radiation-free, easily available, cost-effective way of determining fatty infiltration of liver. The examination can be performed using a 2-5 MHz convex transducer. The normal liver parenchyma has a homogeneous echotexture with echogenicity equal to or slightly greater than that of the renal cortex and spleen. The liver shows echogenicity higher than the renal cortex and spleen due to fatty infiltration. [5] Various (0-3) grades of steatosis have been proposed based on visual analysis of the intensity of the echogenicity, provided that the gain setting is optimum [Figure 2]. When the echogenicity is just increased, it is grade I; when the echogenic liver obscures the echogenic walls of portal vein branches, it is grade II, and, when the echogenic liver obscures the diaphragmatic outline, it is grade III fatty infiltration. [6] These are however subject to inter-observer variation. The sensitivity of USG in detecting hepatic steatosis ranges from 60 to 94% and the specificity from 84 to 95%. [7],[8],[9] Hepatorenal sonographic index, which is the ratio between the mean brightness level of the liver and the right kidney, has also been proposed as a measure of hepatic steatosis with a cut-off of 1.49, yielding very high sensitivity (100%) and specificity (91%) for the diagnosis of steatosis >5%. [10] Transient elastography/Fibroscan and acoustic radiation force impulse (ARFI) elastography can be integrated into the conventional USG system. These have emerged as new kids on the block to grade the extent of liver stiffness.
Figure 2: Grades of fatty liver on visual analysis. Ultrasound image shows (a) Normal liver echogenicity (b) Grade 1 fatty liver with increased liver echogenicity (c) Grade 2 fatty liver with the echogenic liver obscuring
the echogenic walls of the portal venous branches (d) Grade 3 fatty liver in which the diaphragmatic outline is obscured

Click here to view



Sonoelastography provides an estimation of liver stiffness that in turn is affected by fat infiltration and includes techniques such as ARFI and transient elastography. ARFI imaging involves targeting an anatomic region to be examined for its elastic properties by using a region-of-interest cursor while performing real-time B-mode imaging. The measured shear wave speed is an intrinsic and reproducible property of tissue. By observing the shear wave front at several locations and correlating these measurements with the elapsed time, the shear wave speed can be quantified. Tracking beams, which are sensitive to greater than 1/100 the wavelength of sound, are applied adjacent to the push pulse path. These beams are continuously transmitted until the passing shear wave front is detected. The time between the generation of the shear wave and the detection of the peak is used to compute the shear wave velocity. In transient elastography, a pulse-echo acquisition is performed to follow the propagation of the shear wave and measure its velocity, which is directly related to the tissue stiffness (or elastic modulus). The results are expressed in kilopascals (kPa). The harder the tissue, the faster the propagation of the shear wave. [11],[12]


Transient elastography/Fibroscan measures liver stiffness as a function of the extent of hepatic infiltration. It is performed with a curved array US probe at 4 MHz for B-mode imaging. The patient is positioned supine on the couch with the right arm in maximum abduction, which makes the right hypochondrium accessible. Normal breathing is recommended. The tip of the transducer is covered with 5 mm of USG gel and placed on the skin in the selected intercostal space with a pressure of the probe such that it is absorbed by the ribs without impacting the soft tissue. B-mode image is obtained by avoiding the rib shadowing and focusing on the right lobe of the liver. After ensuring the best possible contact between the probe and the skin, a switch to elastography mode is made and shear wave elastography (SWE) box is obtained. The box is moved onto a vessel-free region of liver parenchyma, which is defined by the B-mode image. An area where the liver tissue is at least 6-cm thick and free of large blood vessels is selected. A measurement depth of 2 cm below the liver capsule may be chosen to standardize the examination. The quantification is then performed by choosing a size ranging from 15 to 20 mm, preferably in the central area of the SWE box having an area of relative homogeneous elasticity displayed in different colors [Figure 3]. The shear stiffness of normal liver is between 6.5 and 7 kPa. Several (as many as ten) successful acquisitions should be performed in each patient, and the median value should be determined and used as a representative measurement of the liver elasticity.
Figure 3: Shear wave elastography. Sonoelastography image (a) shows normal liver with mean stiffness value of 7.0 kilopascal (b) grade 1 fatty liver showing decrease in the mean stiffness value to 6.1 kilopascal

Click here to view

ARFI is also performed in a similar fashion, and it measures shearing velocity. Normal velocity of liver is 1 m/s. This velocity decreases once there is fatty infiltration [Figure 4].
Figure 4: Acoustic radiation force impulse (ARFI) elastography. Sonoelastography image shows grade 2 fatty liver with decrease in shearing velocity (0.80 m/sec). The shearing velocity in normal liver parenchyma is 1 m/s

Click here to view

Computed tomography

Steatosis causes reduced attenuation of liver on CT, which can be represented quantitatively by comparing it with the attenuation of spleen on unenhanced scans. A liver-to-spleen attenuation ratio of <0.8 has a high specificity (100%) for diagnosis of moderate to severe steatosis. From the assessment of hepatic steatosis in transplant donors, it has been concluded that unenhanced CT performs very well in diagnosing steatosis of ≥ 30%, with 100% specificity and 82% sensitivity. [13] Calculating the difference between the attenuation of the spleen and that of the liver can also be used to evaluate steatosis. The attenuation of the spleen is approximately 8-10 HU less than that of the liver in a normal individual, whereas a liver-to-spleen attenuation difference >10 HU is a strong predictor of hepatic steatosis. [14] It is a quick, non-operator dependent technique. Radiation exposure can be kept at a minimum by using low-dose protocols.

Dual-energy CT can also be used to quantify hepatic fat. It involves acquisition at two tube potentials, namely, 80 and 140 kVp. The estimation of tissue composition is possible due to the difference in the attenuation characteristics of different substances. In hepatic steatosis, there is a decrease in CT attenuation of liver at low energy level. As the tube potential increases, the fat attenuation increases. Studies have found that an attenuation change of >10 HU with increase in tube potential from 80 to 140 kVp is suggestive of fatty infiltration of >25%. [15]


The degree of decrease in attenuation on unenhanced CT is the best predictor of the degree of fatty infiltration in the liver. [16]


Low-dose, unenhanced CT (80 kV, 100 mAs with dose modulation, collimation of 128 × 0.625, 10-mm section thickness) is performed. For each case, the hepatic attenuation [Figure 5] is measured by means of a random selection of circular regions of interest (ROIs) on both lobes. For each ROI, the largest possible ROI is selected by avoiding areas of visible hepatic vascular and biliary structures. ROIs may range from 200 to 400 mm΂. The ROI values are averaged as a mean hepatic attenuation. To provide an internal control, the mean splenic attenuation is also calculated by averaging three random ROI values of splenic attenuation measurement. The largest possible ROI (size range: 200-400 mm 2 ) is selected to represent splenic parenchymal attenuation. The liver attenuation index (LAI) is derived from the difference between mean hepatic attenuation and mean splenic attenuation and can be used as a parameter for prediction of the degree of macrovesicular steatosis. A difference in attenuation of the liver and spleen of 10 HU is taken as normal.
Figure 5: CT for detection of liver fat. Image shows (a) normal liver with attenuation greater than spleen on visual analysis (b) multiple ROIs for measurement of attenuation of liver and spleen, mean hepatic attenuation
is 67 HU and mean splenic attenuation is 48.5 HU, hence, liver attenuation index LAI is 18.5 HU which is normal (c) diffuse fatty infi ltration of liver with hepatic attenuation markedly less than the spleen (d) multiple ROIs show mean hepatic attenuation of – 15.8 HU and mean splenic attenuation of 42.5 HU with LAI of -58.3 HU suggestive of marked fatty infi ltration of liver

Click here to view

Magnetic resonance imaging

MRI is a radiation-free modality to detect hepatic fat even in microscopic quantity. Various techniques like CSI, proton spectroscopy, and MR elastography can be utilized. The sensitivity and specificity of CSI is 90% and 91%, while that of spectroscopy is 91% and 87%, respectively. [17] MR elastography can be used to measure liver stiffness. However, MRI is a relatively time consuming and costly procedure.


CSI is based on the fact that during echo time (TE), the transverse magnetization vectors of fat and water develop a phase difference that results in decreased overall length of the magnetization vector under opposed phase (OP) conditions. At the main magnetic field strength of 1.5 T, the frequency shift between fat and water is approximately 220 Hz, which results in OP condition at a TE of about 2.4 ms and in-phase (IP) condition at a TE of about 4.8 ms. Typically, the fatty liver shows increase in signal intensity (SI) on IP images and shows diffuse signal drop in OP image. The fat fraction can then be determined by calculating the loss of SI in OP images as compared to IP images [Figure 6]. From congruent sets of IP and OP images, acquired within the same breath-hold, the fat fraction can be calculated pixel-wise, and misregistration errors can be avoided. Thus, maps of intrahepatic fat fraction and fat signal percentage can be obtained to estimate liver fat content and show differences in regional fat distribution. A commonly used formula for calculating the hepatic fat signal percentage (FSP) is [(SI IP − SI OP )/2SI IP ×100. Where, SI IP is the ratio of hepatic to splenic SI in the IP image and SI OP is the ratio of hepatic to splenic SI in the T1-weighted OP image. Breath-hold gradient-echo (GRE) is the chemical shift technique routinely used for fat estimation. However, GRE sequences are susceptible to the paramagnetic effects of iron. Hence, Dixon put forth the two-point method for CSI using spin echo (SE) sequence. The IP images were the unmodified SE images, whereas the OP images were generated by offsetting the rephasing pulse in a SE sequence. Summation and subtraction yielded the water-only and fat-only images, which could be used for direct quantification. [18],[19],[20] The limitation of this technique was its long acquisition time and sensitivity to magnetic field inhomogeneities. To overcome these, a three-point Dixon method was introduced, which involved acquisition of a third set of images besides the in- and opposed-phase images.
Figure 6: Chemical shift imaging. MRI image shows (a) in-phase image witha hepatic to splenic signal intensity ratio of 1.6 (b) opposed- phase shows signal drop in liver due to diffuse fatty infiltration

Click here to view

Modified GRE techniques have been developed to decrease acquisition time and to eliminate misregistration and susceptibility to magnetic field inhomogeneities. With these techniques, the IP and OP images are acquired within a matter of milliseconds by using different TEs in the same acquisition. The advantages of CSI are coverage of the entire liver.

Two main strategies are used for single-voxel spectroscopy (SVS), namely, point-resolved spectroscopy (PRESS) or stimulated-echo acquisition mode (STEAM). [21] The PRESS acquisition scheme (multi-echo single-shot technique) uses a 90°-180°-180° pulse sequence with long TE and allows better visualization of metabolites with long T1 relaxation times. In contrast, the STEAM sequence applies a 90°-90°-90° pulse sequence and is less sensitive to J-coupling effects. The STEAM sequence provides shorter TE and lower signal yield as compared to PRESS, which is usually not a limitation for fat quantification in the liver.


MRI with CSI involves acquisition of T1-weighted IP and OP images. The SI is measured by mean ROI placed at same locations in both phases. Several (as many as 12) ROIs may be placed in the liver at three levels, with four ROIs at each level (two in the right lobe and two in the left lobe) on anatomically matched locations on the IP and out-of-phase T1-weighted MRI. All of the ROIs should have an area between 1.5 and 2 cm 2 (volume, 1.2-1.6 cm 3 ) and should avoid major vessels, organ edges, or visual artifacts. The ROIs can be placed superior, inferior, and at the level of the portal vein. This generates a maximum of 12 ROIs in the liver on both the IP and out-of-phase images, which are averaged together to create the average SI value of the IP image and out-of-phase image. Fat-water ratio can be obtained by dividing SI of liver in OP sequence by SI of liver in IP sequence.

MR spectroscopy (MRS) shows an increase in the intensity of the lipid resonance peak in the presence of steatosis at 1.9-2.3 parts per million (ppm), 1.1-1.5 ppm, and 0.8-1.1 ppm [Figure 7]. Because MRS allows the direct measurement of the area under the lipid resonance peak, it can be used to provide a quantitative assessment of fatty infiltration of the liver. It is also unaffected by confounding factors like fibrosis, iron overload, and glycogen. However, it is a complex technique that requires patient co-operation and samples only a small portion of the entire liver.
Figure 7: MR Spectroscopy PRESS. Image shows a lipid peak (white arrow) in a case of hepatic steatosis

Click here to view

To conclude, NAFLD is significant cause of chronic liver disease and is now regarded as hepatic manifestation of the metabolic syndrome. The morbidity and mortality related to NAFLD is expected to rise with the upsurge of obesity and type 2 diabetes mellitus. The need of the hour is to devise techniques to estimate and then accurately follow-up hepatic fat content in patients with NAFLD. Since efforts are underway to treat this condition, it is of paramount importance to come up with accurate, reproducible, and non-invasive means of estimating liver fat. Imaging modalities like sonoelastography, CT, and MRI are the front runners in quantification of hepatic steatosis in this manner and may do away with the need of an invasive liver biopsy for this indication in the near future.

   References Top

1.Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.  Back to cited text no. 1
2.Duseja A. Nonalcoholic fatty liver disease in India: A lot done, yet more required! Indian J Gastroenterol 2010;29:217-25.  Back to cited text no. 2
3.Manco M, Bottazzo G, DeVito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic fatty liver disease in children. J Am Coll Nutr 2008;27:667-76.  Back to cited text no. 3
4.Edmison J, McCullough AJ. Pathogenesis of non-alchoholic steatohepatitis: Human data. Clin Liver Dis 2007;11:75-104.  Back to cited text no. 4
5.Valls C, Iannacconne R, Alba E, Murakami T, Hori M, Passariello R, et al. Fat in the liver: Diagnosis and characterization. Eur Radiol 2006;16:2292-308.  Back to cited text no. 5
6.Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.  Back to cited text no. 6
7.Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26-31.  Back to cited text no. 7
8.Debongnie JC, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut 1981;22:130-5.  Back to cited text no. 8
9.Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5.  Back to cited text no. 9
10.Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009;192:909-14.  Back to cited text no. 10
11.Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010;256:640-7.  Back to cited text no. 11
12.Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.  Back to cited text no. 12
13.Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: Use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-12.  Back to cited text no. 13
14.Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: Its usefulness in predicting the presence of diffuse liver disease. Radiology 1980;137:727-9.  Back to cited text no. 14
15.Raptopoulos V, Karellas A, Bernstein J, Reale FR, Constantinou C, Zawacki JK. Value of dual-energy CT in differentiating focal fatty infiltration of the liver from low-density masses. Am J Roentgenol 1991;157:721-5.  Back to cited text no. 15
16.Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, Abdalla EK, et al. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol 2007;188:1307-12.  Back to cited text no. 16
17.van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, Ten Kate FJ, van Gulik TM, et al. Assessment of hepatic steatosis in patients undergoing liver resection: Comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010;256:159-68.  Back to cited text no. 17
18.Dixon WT. Simple proton spectroscopic imaging. Radiology 1984;153:189-94.  Back to cited text no. 18
19.Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 1997;15:287-93.  Back to cited text no. 19
20.Ma X, Holalkere NS, Kambadakone RA, Mino-Kenudson M, Hahn PF, Sahani DV. Imaging-based quantification of hepatic fat: Methods and clinical applications. Radiographics 2009;29:1253-77.  Back to cited text no. 20
21.Skoch A, Jiru F, Bunke J. Spectroscopic imaging: Basic principles. Eur J Radiol 2008;67:230-9.  Back to cited text no. 21


  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]

This article has been cited by
1 Liver Abnormalities in Systemic Lupus Erythematosus: A Prospective Observational Study
Shaik Imran,Molly Mary Thabah,Mohamed Azharudeen,Ananthakrishnan Ramesh,Zachariah Bobby,Vir S Negi
Cureus. 2021;
[Pubmed] | [DOI]
2 Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review
Michael J. Trujillo,Johnson Chen,Jonathan M. Rubin,Jing Gao
Clinical Imaging. 2021; 78: 22
[Pubmed] | [DOI]
3 A Study on Association between Neutrophil to Lymphocyte Ratio and Steatohepatitis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
Jayachandra Jayachandra,Sree Raksha K.N,Rakshit R. Desai,Chetan V,Arjun P. Chandrashekar
Journal of Evolution of Medical and Dental Sciences. 2021; 10(25): 1876
[Pubmed] | [DOI]
4 Non-alcoholic fatty liver disease in patients with hypothyroidism presenting at a rural tertiary care centre in north India
Harpreet Grewal,Sandeep Joshi,Ruby Sharma,Puneet Mittal,Ankur Goel
Tropical Doctor. 2021; 51(2): 181
[Pubmed] | [DOI]
5 Effect of Chemotherapy on Fatty Liver Occurrence in Breast and Gastrointestinal Cancer Patients: A Case-Controlled Study
Payam Izadpanahi,Mahyar Mohammadifard,Tahmine Tavakoli,Najmeh Abbasi,Seyed Alireza Javadinia
Hepatitis Monthly. 2020; 20(3)
[Pubmed] | [DOI]
6 The association between vitamin D status and non-alcoholic fatty liver disease in adults: a hospital-based study
Ahmed Ibrahim Gad,Mohamed Rezk Elmedames,Ayman Ramadan Abdelhai,Ayman Mohamed Marei
Egyptian Liver Journal. 2020; 10(1)
[Pubmed] | [DOI]
7 Screening of NAFLD family members can detect undiagnosed NAFLD cases: Is there a genetic link?
Shubham Jain,Ravi Thanage,Suhas S. Udgirkar,Sanjay J. Chandnani,Pravin M. Rathi,Qais Q. Contractor,Nair P. Sujit,Partha Debnath,Falguni Panchal,Renuka Munshi,Anupam Singh
Journal of Clinical and Experimental Hepatology. 2020;
[Pubmed] | [DOI]
8 Food groups and the likelihood of non-alcoholic fatty liver disease: a systematic review and meta-analysis
Kaiyin He,Yuting Li,Xin Guo,Lu Zhong,Shaohui Tang
British Journal of Nutrition. 2020; : 1
[Pubmed] | [DOI]
Konuralp Tip Dergisi. 2020; : 44
[Pubmed] | [DOI]
10 The prevalence and correlates of T-wave inversion in lead III in non-obese men
Cihan Sengul,Cayan Cakir,Suleyman Barutcu,Remzi Sarikaya
Journal of Electrocardiology. 2020;
[Pubmed] | [DOI]
11 Prevalence of Nonalcoholic Fatty Liver Disease in Familial Mediterranean Fever
Turker Tasliyurt,Erkan Gokce,Safak Sahin,Asiye Baris Aslan,Ayse Kevser Demir,Suheyla Uzun,Faruk Kutluturk
Endocrine, Metabolic & Immune Disorders - Drug Targets. 2020; 20(6): 952
[Pubmed] | [DOI]
12 Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents
Vandana Jain,Anil Kumar,Nayeem Ahmad,Manisha Jana,Mani Kalaivani,Brijesh Kumar,Shivaram Shastri,Oshima Jain,Madhulika Kabra
Journal of Pediatric Endocrinology and Metabolism. 2019; 32(7): 749
[Pubmed] | [DOI]
13 Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study
Jeong-Ju Yoo,Yang Jae Yoo,Woo Ram Moon,Seung Up Kim,Soung Won Jeong,Ha Na Park,Min Gyu Park,Jae Young Jang,Su Yeon Park,Beom Kyung Kim,Jun Yong Park,Do Young Kim,Sang Hoon Ahn,Kwang-Hyub Han,Sang Gyune Kim,Young Seok Kim,Ji Hoon Kim,Jong Eun Yeon,Kwan Soo Byun
The Korean Journal of Internal Medicine. 2019;
[Pubmed] | [DOI]
14 Current status of imaging in nonalcoholic fatty liver disease
Qian Li,Manish Dhyani,Joseph R Grajo,Claude Sirlin,Anthony E Samir
World Journal of Hepatology. 2018; 10(8): 530
[Pubmed] | [DOI]
15 Dietary patterns and non-alcoholic fatty liver disease in a Greek case-control study
Ioanna Panagiota Kalafati,Dimitra Borsa,Maria Dimitriou,Konstantinos Revenas,Alexander Kokkinos,George Dedoussis
Nutrition. 2018;
[Pubmed] | [DOI]
16 Corneal endothelial alterations in alcohol dependence syndrome
Alok Sati,Parthasarathi Moulick,Sandeep Shankar,Kaushik Chatterjee,Arun Kumar Dwivedi,Jayesh Vazirani
British Journal of Ophthalmology. 2018; 102(10): 1443
[Pubmed] | [DOI]
17 Cognitive Changes and Brain Volume Reduction in Patients with Nonalcoholic Fatty Liver Disease
Branka Filipovic,Olivera Markovic,Vesna Ðuric,Branislav Filipovic
Canadian Journal of Gastroenterology and Hepatology. 2018; 2018: 1
[Pubmed] | [DOI]
18 Grading fatty liver by ultrasound time-domain radiofrequency signal analysis: an in vivo study of rats
Wenwu Ling,Jierong Quan,Jiangli Lin,Tingting Qiu,Jiawu Li,Qiang Lu,Changli Lu,Yan Luo
Experimental Animals. 2018; 67(2): 249
[Pubmed] | [DOI]
19 Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a case–control study
I. P. Kalafati,M. Dimitriou,D. Borsa,J. Vlachogiannakos,K. Revenas,A. Kokkinos,S. D. Ladas,G. V. Dedoussis
European Journal of Nutrition. 2018;
[Pubmed] | [DOI]
20 Multi-modal framework for automatic detection of diagnostically important regions in nonalcoholic fatty liver ultrasonic images
R. Bharath,P. Rajalakshmi,Mohammad Abdul Mateen
Biocybernetics and Biomedical Engineering. 2018;
[Pubmed] | [DOI]
21 Investigation of Blood Betatrophin Levels in Obese Children with Non-Alcoholic Fatty Liver Disease
Fatih Battal,Hakan Türkön,Nilüfer Aylanç,Hakan Aylanç,Sule Yildirim,Nazan Kaymaz,Sema Uysal
Pediatric Gastroenterology, Hepatology & Nutrition. 2018; 21(2): 111
[Pubmed] | [DOI]
22 Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assessment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients
Tamara Milovanovic Alempijevic,Milica Stojkovic Lalosevic,Igor Dumic,Nevena Jocic,Aleksandra Pavlovic Markovic,Sanja Dragasevic,Ivana Jovicic,Snezana Lukic,Dragan Popovic,Tomica Milosavljevic
Canadian Journal of Gastroenterology and Hepatology. 2017; 2017: 1
[Pubmed] | [DOI]
23 Computer-aided Characterization and Diagnosis of Diffuse Liver Diseases Based on Ultrasound Imaging
Puja Bharti,Deepti Mittal,Rupa Ananthasivan
Ultrasonic Imaging. 2017; 39(1): 33
[Pubmed] | [DOI]
24 Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods
AM Lapadat,IR Jianu,BS Ungureanu,LM Florescu,DI Gheonea,S Sovaila,IA Gheonea
Journal of Medicine and Life. 2017; 10(1): 19
[Pubmed] | [DOI]
25 High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments
Hsiao-Ching Nien,Shih-Jer Hsu,Tung-Hung Su,Po-Jen Yang,Jin-Chuan Sheu,Jin-Town Wang,Lu-Ping Chow,Chi-Ling Chen,Jia-Horng Kao,Wei-Shiung Yang,Tatsuo Kanda
PLOS ONE. 2017; 12(1): e0170028
[Pubmed] | [DOI]
26 Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes
Mabel Graffigna,Natalia Catoira,Jimena Soutelo,Andreína Azpelicueta,Gabriela Berg,Cecilia Perel,Marta Elena Migliano,Marcela Aranguren,Carla Musso,Javier Farias
Revista Argentina de Endocrinología y Metabolismo. 2017;
[Pubmed] | [DOI]
27 The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease
Jeong In Lee,Min Chul Kim,Byung Sub Moon,Young Seok Song,Eun Na Han,Hyo Sun Lee,Yoonjeong Son,Jihyun Kim,Eun Jin Han,Hye-Jeong Park,Se Eun Park,Cheol-Young Park,Won-Young Lee,Ki-Won Oh,Sung-Woo Park,Eun-Jung Rhee
Endocrinology and Metabolism. 2016; 31(1): 86
[Pubmed] | [DOI]
28 Protective effect of ursodeoxycholic acid, resveratrol, andN-acetylcysteine on nonalcoholic fatty liver disease in rats
Mahmoud Hussein Hassan Ali,Basim Anwar Shehata Messiha,Hekma Abdel-Tawab Abdel-Latif
Pharmaceutical Biology. 2015; : 1
[Pubmed] | [DOI]
29 Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol
Jennifer E. Lambert,Jill A. Parnell,Bertus Eksteen,Maitreyi Raman,Marc R. Bomhof,Kevin P. Rioux,Karen L. Madsen,Raylene A. Reimer
BMC Gastroenterology. 2015; 15(1)
[Pubmed] | [DOI]
30 Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease
Mustafa Koplay
World Journal of Hepatology. 2015; 7(5): 769
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   Imaging Modalities
    Article Figures

 Article Access Statistics
    PDF Downloaded2174    
    Comments [Add]    
    Cited by others 30    

Recommend this journal